Parallel Industries Inc.
EAPH
Other OTC0.00
USD
- -
- -
CIK
0001071272
ISIN
US2777741057
CUSIP
277774105
Return %
Stock
S&P500
1Y
100.00
26.53
3Y
- -
76.60
5Y
-96.00
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Evan Karras
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 111 Brockhouse Road Toronto ON Canada
- IPO Date
- Sep 13, 1999
- CIK
- 0001071272
- Website
- eastonpharma.com
- Similar Companies
- Business
- Parallel Industries Inc. is a development-stage pharmaceutical company engaged in the development, licensing, production, and marketing of prescription and over-the-counter pharmaceutical products. The company's product portfolio includes prescription and therapeutic topical drugs and healthcare products targeting cancer treatment and various other conditions such as female sexual dysfunction, wound healing, pain relief, and motion sickness. Key products include Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream; Kenestrin Gel for pain relief; Viorra, an aid for female sexual arousal disorder; and XILIVE, an early-stage cancer drug candidate incorporating its proprietary Viorra Delivery Matrix technology. The company was formerly known as Easton Pharmaceuticals Inc. and rebranded as Parallel Industries Inc. in December 2020. Founded in 1997, it is headquartered in Toronto, Canada. Parallel Industries operates primarily in the specialty and generic drug manufacturing segment within the healthcare industry. The company markets and distributes products mainly in Canada, with ongoing efforts towards commercialization and product development. Recent major developments include the company’s strategic focus on advancing its pipeline of topical and therapeutic products and actively pursuing commercialization stages of its existing pharmaceuticals. While the company currently does not report significant operations or revenues, it continues research on its product candidates and maintains a lean organizational structure composed of a small number of employees. There have been no public announcements of recent funding rounds, acquisitions, or major strategic partnerships within the last 1-2 years. However, the company retains a core emphasis on proprietary drug delivery technologies and expanding its product offerings in oncology, pain management, and women's health. Parallel Industries serves niche healthcare markets with prescription drugs and over-the-counter therapeutic solutions that aim to address unmet medical needs through topical drug delivery technologies. Its efforts encompass drug development, licensing agreements, production, and marketing activities focused on the North American pharmaceutical market. This concise profile reflects the latest available data on Parallel Industries Inc., capturing its core products, recent organizational changes, and industry positioning as of late 2025.